Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Angelika Geroldinger is active.

Publication


Featured researches published by Angelika Geroldinger.


International Journal of Cardiology | 2017

Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014

Safoura Sheikh Rezaei; Angelika Geroldinger; Georg Heinze; Berthold Reichardt; Michael Wolzt

BACKGROUND The beneficial use of dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and P2Y12 õinhibitors has been established for patients after acute coronary syndrome (ACS). However, the optimal duration of DAPT is under debate. The aim of the present study was to investigate the long-term utilization and clinical outcome of clopidogrel, prasugrel, and ticagrelor in patients with ACS from 2009 to 2014 in Austria. METHODS We analysed data from 13 Austrian health insurance funds for the years 2009 to 2014, on 72,676 patients with a hospital discharge diagnosis of ACS. The primary end point was recurrence of ACS or death >30days after the index event. RESULTS 32,830 subjects received a prescription of a P2Y12 inhibitor within 30days after the index ACS. 18,640 (56.8%) subjects were discharged with clopidogrel, 6683 (20.4%) with prasugrel, and 7507 (22.9%) with ticagrelor, respectively. Data from 32,174 patients with 4975 events during a median follow-up period of 24.9months were available for survival analysis. The cumulative incidence for recurrence of ACS or death at two years was 18.7% in patients receiving clopidogrel, and 8.7% and 12.0% in those receiving prasugrel or ticagrelor, respectively. CONCLUSION Utilization of P2Y12 inhibitors in patients with ACS was consistent with guideline recommendations. Prasugrel and ticagrelor are increasingly used in ACS patients and associated with a lower number of recurrence of ACS or death compared to clopidogrel. However, clopidogrel was predominantly used in older patients with more co-morbidities.


Nephrology Dialysis Transplantation | 2015

Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025

Alexander Kainz; Milan Hronsky; Vianda S. Stel; Kitty J. Jager; Angelika Geroldinger; Daniela Dunkler; Georg Heinze; Giovanni Tripepi; Rainer Oberbauer

BACKGROUND Diabetes and chronic kidney disease (CKD) are a growing burden for health-care systems. The prevalence of diabetes has increased constantly during the last decade, although a slight flattening of end-stage renal disease as a result of diabetes has been observed recently in some European countries. In this study, we project the prevalence of CKD in patients with diabetes in European countries up to the year 2025. METHODS We analysed the population with diabetes and development of nephropathy in 12 European countries, which we computed from models published previously and on data from the annual reports of the European Renal Association (1998-2011). The prevalence of CKD stage 5 in patients with diabetes up to the year 2025 was projected by the Lee-Carter algorithm. Those for stage 3 and 4 were then estimated by applying the same ratios of CKD prevalences as estimated in the Austrian population with diabetic nephropathy. RESULTS The estimated prevalence of CKD in patients with diabetes is expected to increase in all 12 countries up to the year 2025. For CKD stage 3, we estimate for Austria in 2025 a prevalence of 215 000 per million diabetic population (p.m.p.) (95% confidence interval 169 000, 275 000), for CKD4 18 600 p.m.p. (14 500, 23 700) and for CKD5 6900 p.m.p. (5400, 8900). The median prevalence in the considered countries is 132 900 p.m.p. (IQR: 118 500, 195 800), 11 500 (10 200, 16 900) and 4300 (3800, 6300) for CKD stages 3, 4 and 5, respectively. Altogether, these data predict in the years 2012-25 an annual increase of 3.2% in the prevalence of diabetic CKD stage 5. CONCLUSIONS Due to the increase in prevalence of diabetes and CKD5, the costs of renal therapy are expected to rise. We believe that these data may help health-care policy makers to make informed decisions.


Anesthesiology | 2016

Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial.

Regina P. Schukro; Matthias J. Oehmke; Angelika Geroldinger; Georg Heinze; Hans-Georg Kress; Sibylle Pramhas

Background:Among patients with chronic low back pain (CLBP), approximately 37% show signs of a neuropathic pain component (radicular pain). Treatment of this condition remains challenging. Therefore, the current study aimed to investigate the efficacy of duloxetine in the treatment of CLBP patients with neuropathic leg pain. Methods:The study was conducted as a prospective, randomized, placebo-controlled, double-blind crossover trial. CLBP with a visual analog scale (VAS) score greater than 5 and a neuropathic component that was assessed clinically and by the painDETECT questionnaire (score > 12) were required for inclusion. Patients were randomly assigned to either duloxetine or placebo for 4 weeks followed by a 2-week washout period before they crossed over to the alternate phase that lasted another 4 weeks. Duloxetine was titrated up to 120 mg/day. The primary outcome parameter was mean VAS score during the last week of treatment in each phase (VASweek4). Results:Of 41 patients, 21 patients completed both treatment phases. In the intention-to-treat analysis (n = 25), VASweek4 was significantly lower in the duloxetine phase compared with placebo (4.1 ± 2.9 vs. 6.0 ± 2.7; P = 0.001), corresponding to an average pain reduction of 32%. The painDETECT score at the end of each treatment phase was significantly lower in the duloxetine phase compared with placebo (17.7 ± 5.7 vs. 21.3 ± 3.6 points; P = 0.0023). Adverse events were distributed equally between the duloxetine (65%) and placebo phases (62%) (P = 0.5). Conclusion:In this crossover study, duloxetine proved to be superior to placebo for the treatment of CLBP with a neuropathic leg pain.


American Journal of Epidemiology | 2018

Separation in Logistic Regression: Causes, Consequences, and Control

Mohammad Ali Mansournia; Angelika Geroldinger; Sander Greenland; Georg Heinze

Separation is encountered in regression models with a discrete outcome (such as logistic regression) where the covariates perfectly predict the outcome. It is most frequent under the same conditions that lead to small-sample and sparse-data bias, such as presence of a rare outcome, rare exposures, highly correlated covariates, or covariates with strong effects. In theory, separation will produce infinite estimates for some coefficients. In practice, however, separation may be unnoticed or mishandled because of software limits in recognizing and handling the problem and in notifying the user. We discuss causes of separation in logistic regression and describe how common software packages deal with it. We then describe methods that remove separation, focusing on the same penalized-likelihood techniques used to address more general sparse-data problems. These methods improve accuracy, avoid software problems, and allow interpretation as Bayesian analyses with weakly informative priors. We discuss likelihood penalties, including some that can be implemented easily with any software package, and their relative advantages and disadvantages. We provide an illustration of ideas and methods using data from a case-control study of contraceptive practices and urinary tract infection.


Statistics in Medicine | 2017

Firth's logistic regression with rare events: accurate effect estimates and predictions?

Rainer Puhr; Georg Heinze; Mariana Nold; Lara Lusa; Angelika Geroldinger

Firths logistic regression has become a standard approach for the analysis of binary outcomes with small samples. Whereas it reduces the bias in maximum likelihood estimates of coefficients, bias towards one-half is introduced in the predicted probabilities. The stronger the imbalance of the outcome, the more severe is the bias in the predicted probabilities. We propose two simple modifications of Firths logistic regression resulting in unbiased predicted probabilities. The first corrects the predicted probabilities by a post hoc adjustment of the intercept. The other is based on an alternative formulation of Firths penalization as an iterative data augmentation procedure. Our suggested modification consists in introducing an indicator variable that distinguishes between original and pseudo-observations in the augmented data. In a comprehensive simulation study, these approaches are compared with other attempts to improve predictions based on Firths penalization and to other published penalization strategies intended for routine use. For instance, we consider a recently suggested compromise between maximum likelihood and Firths logistic regression. Simulation results are scrutinized with regard to prediction and effect estimation. We find that both our suggested methods do not only give unbiased predicted probabilities but also improve the accuracy conditional on explanatory variables compared with Firths penalization. While one method results in effect estimates identical to those of Firths penalization, the other introduces some bias, but this is compensated by a decrease in the mean squared error. Finally, all methods considered are illustrated and compared for a study on arterial closure devices in minimally invasive cardiac surgery. Copyright


Cancer Letters | 2015

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer

Caroline Kreuzinger; Magdalena Gamperl; Andrea Wolf; Georg Heinze; Angelika Geroldinger; Diether Lambrechts; Bram Boeckx; Dominiek Smeets; Reinhard Horvat; Stefanie Aust; Gerhard Hamilton; Robert Zeillinger; Dan Cacsire Castillo-Tong

Cancer cell lines are good in vitro models to study molecular mechanisms underlying chemoresistance and cancer recurrence. Recent works have demonstrated that most of the available ovarian cancer cell lines are most unlikely high grade serous (HGSOC), the major type of epithelial ovarian cancer. We aimed at establishing well characterized HGSOC cell lines, which can be used as optimal models for ovarian cancer research. We successfully established seven cell lines from HGSOC and provided the major genomic alterations and the transcriptomic landscapes of them. They exhibited different gene expression patterns in the key pathways involved in cancer resistance. Each cell line harbored a unique TP53 mutation as their corresponding tumors and expressed cytokeratins 8/18/19 and EpCAM. Two matched lines were established from the same patient, one at diagnosis and being sensitive to carboplatin and the other during chemotherapy and being resistant. Two cell lines presented respective BRCA1 and BRCA2 mutations. To conclude, we have established seven cell lines and well characterized them at genomic and transcriptomic levels. They are optimal models to investigate the molecular mechanisms underlying the progression, chemo resistance and recurrence of HGSOC.


Thrombosis Research | 2015

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients

Daniela Bianconi; Alexandra Schuler; Clemens Pausz; Angelika Geroldinger; Alexandra Kaider; Heinz-Josef Lenz; Gabriela Kornek; Werner Scheithauer; Christoph Zielinski; Ingrid Pabinger; Cihan Ay; Gerald W. Prager

Background Integrin β3 is involved in tumor and endothelial cell biology as well as in platelet aggregation. Herein, we evaluated the predictive potential of three germline single nucleotide polymorphisms (SNPs) in the integrin β3 gene (rs3809865, rs5918 and rs4642) to predict the risk of venous thromboembolism (VTE) in colorectal cancer (CRC) patients, which is one of the leading causes of death among cancer patients. Methods 112 patients diagnosed with CRC enrolled in the prospective Vienna Cancer and Thrombosis Study (CATS) were assessed with a median follow-up of 46 months. DNA was isolated from venous blood samples and SNPs were analyzed by the PCR-RFLP method. Results VTE occurred in 12% (n = 13) of all patients. The SNPs rs5918 and rs4642 were not associated with VTE risk. For rs3809565, 23% (n = 11) of patients had the A/A genotype, 4% (n = 2) had the A/T genotype, but none (0%) had the T/T genotype. In the univariate analysis, patients with the A/A genotype had a significantly higher risk to develop VTE compared to the other polymorphisms (P = 0.0005 after Fine and Gray). In the multivariable analysis, the predictive value remained significant. Conclusions This study identified the rs3809865 A/A genotype as an independent risk factor for VTE in CRC patients. Our findings would help identify high risk patients and would be essential for tailored anticoagulant prophylaxis.


American Journal of Physiology-endocrinology and Metabolism | 2015

Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counterregulation.

Yvonne Winhofer; Martin Krssak; Peter Wolf; Christian-Heinz Anderwald; Angelika Geroldinger; Georg Heinze; Sabina Baumgartner-Parzer; Rodrig Marculescu; Thomas M. Stulnig; Michael Wolzt; Siegfried Trattnig; Anton Luger; Michael Krebs

Hypoglycemia, a major side effect of intensive glucose-lowering therapy, was recently linked to increased cardiovascular risk in patients with diabetes. Whether increased circulating free fatty acids (FFA) owing to catecholamine-induced lipolysis affect myocardial energy metabolism and thus link hypoglycemia to cardiac vulnerability is unclear. Therefore, this study investigated the impact of hypoglycemia counterregulation (± inhibition of lipolysis) on myocardial lipid content (MYCL) and left ventricular function in healthy subjects. Nine healthy men were studied in randomized order: 1) insulin/hypoglycemia test (IHT; ins+/aci-), 2) IHT during inhibition of adipose tissue lipolysis by acipimox (ins+/aci+), 3) normoglycemia with acipimox (ins-/aci+), and 4) normoglycemia with placebo (ins-/aci-). MYCL and cardiac function were assessed by employing magnetic resonance spectroscopy/imaging at baseline and at 2 and 6 h. In response to acute hypoglycemia, plasma FFA (P<0.0001) and ejection fraction (EF; from 63.2±5.5 to 69.6±6.3%, P=0.0001) increased significantly and were tightly correlated with each other (r=0.68, P=0.0002); this response was completely blunted by inhibition of adipose tissue lipolysis. In the presence of normoglycemia, inhibition of lipolysis was associated with a drop in EF (from 59.2±5.5 to 53.9±6.9%,P=0.005) and a significant decrease in plasma FFA, triglycerides, and MYCL (by 48.5%, P=0.0001). The present data indicate that an intact interorgan cross-talk between adipose tissue and the heart is a prerequisite for catecholamine-mediated myocardial contractility and preservation of myocardial lipid stores in response to acute hypoglycemia.


Clinical Cancer Research | 2017

A complex network of tumor microenvironment in human high grade serous ovarian cancer

Caroline Kreuzinger; Angelika Geroldinger; Dominiek Smeets; Elena Ioana Braicu; Jalid Sehouli; Julia Koller; Andrea Wolf; Silvia Darb-Esfahani; Korinna Joehrens; Ignace Vergote; Adriaan Vanderstichele; Bram Boeckx; Diether Lambrechts; Hani Gabra; G. Bea A. Wisman; Fabian Trillsch; Georg Heinze; Reinhard Horvat; Stephan Polterauer; Els M. J. J. Berns; Charles Theillet; Dan Cacsire Castillo-Tong

Purpose: Most high-grade serous ovarian cancer (HGSOC) patients develop recurrent disease after first-line treatment, frequently with fatal outcome. This work aims at studying the molecular biology of both primary and recurrent HGSOC. Experimental Design: Gene expression profiles of matched primary and recurrent fresh-frozen tumor tissues from 66 HGSOC patients were obtained by RNA sequencing. Clustering analyses and pairwise comparison of the profiles between matched samples and subsequent functional alignment were used for the identification of molecular characteristics of HGSOC. Results: Both primary and recurrent HGSOC samples presented predominant gene expression differences in their microenvironment, determined by a panel of genes covering all major pathways of immune activation together with a number of genes involved in the remodeling of extracellular matrix and adipose tissues. Stratifying tumor tissues into immune active and silent groups, we further discovered that although some recurrent tumors shared the same immune status as their primary counterparts, others switched the immune status, either from silent to active or active to silent. Interestingly, genes belonging to the B7-CD28 immune checkpoint family, known for their major role as negative regulators of the immune response, were overexpressed in the immune active tumors. Searching for potential tumor antigens, CEACAM21, a member of the carcinoembryonic antigen family, was found to be significantly overexpressed in immune active tissues in comparison with the silent ones. Conclusions: The results illustrate the complexity of the tumor microenvironment in HGSOC and reveal the molecular relationship between primary and recurrent tumors, which have multiple therapeutic implications. Clin Cancer Res; 23(24); 7621–32. ©2017 AACR.


PLOS ONE | 2018

Mortality and continuity of care – Definitions matter! A cohort study in diabetics

Angelika Geroldinger; Simone Katja Sauter; Georg Heinze; Gottfried Endel; Wolfgang Dorda; Georg Duftschmid

Objective To demonstrate that when investigating the relevance of continuity of care for patient outcomes, different definitions can lead to contradicting results. Methods We used claims data from the regional public health insurer of Lower Austria covering the period from 2008 to 2011. The study sample included subjects with repeated dispensings of anti-diabetic drugs. The continuity of care index was calculated firstly based on a patient’s contacts with general practitioners (primary COCI) and secondly based on contacts at all medical disciplines (total COCI). The association of the two continuity of care measures with mortality was assessed in separate univariable and multivariable Cox regression models. Results Our study sample consisted of 51,717 patients with a median observation time of 3.65 years. The data showed that a high total COCI was associated with increased mortality, while there was no association between primary COCI and mortality. Conclusions Measures of continuity of care are highly sensitive to the type of medical disciplines taken into account. The continuity of care index calculated from contacts at all medical disciplines might measure diversity rather than continuity of care.

Collaboration


Dive into the Angelika Geroldinger's collaboration.

Top Co-Authors

Avatar

Georg Heinze

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Andreas Selberherr

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Christian Scheuba

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Michael Wolzt

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Philipp Riss

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Andrea Wolf

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruno Niederle

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Caroline Kreuzinger

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge